Zoetis Inc. (NYSE:ZTS) Director Sells $201,029.40 in Stock

Zoetis Inc. (NYSE:ZTS) Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zoetis Trading Down 1.0 %

Shares of ZTS stock opened at $160.03 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The firm has a market capitalization of $71.66 billion, a PE ratio of 29.26, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The stock has a fifty day moving average of $166.86 and a two-hundred day moving average of $176.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. Zoetis’s dividend payout ratio is presently 36.56%.

Institutional Investors Weigh In On Zoetis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC acquired a new position in Zoetis during the fourth quarter worth about $30,000. Darwin Wealth Management LLC bought a new stake in Zoetis in the third quarter worth about $31,000. Finally, Capital Performance Advisors LLP acquired a new stake in Zoetis in the 3rd quarter valued at about $33,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZTS. Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Barclays upped their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.